
Eli Lilly (LLY.N) announced the successful outcome of a late-stage study for its experimental drug, mirikizumab, as a potential treatment for moderately to severely active Crohn's disease, a debilitating gastrointestinal disorder. The study revealed that 54.1% of patients who received mirikizumab achieved relief from gastrointestinal symptoms after 52 weeks, compared to only 19.6% on placebo. Additionally, mirikizumab demonstrated non-inferiority to Johnson & Johnson's Stelara managing the disease. Lilly also noted a lower incidence of serious adverse events among mirikizumab recipients than those on a placebo. The company plans to submit this promising data to the FDA in 2024 for potential regulatory approval.
Like
Save
Share